within Pharmacolibrary.Drugs.ATC.S;

model S01EX06
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 0.0024 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EX06</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Omidenepag isopropyl is a selective prostaglandin E2 receptor agonist used as an ophthalmic solution to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first approved in Japan and has gained some approvals in other countries.</p><h4>Pharmacokinetics</h4><p>No published studies have been found describing detailed human pharmacokinetic parameters for omidenepag after ophthalmic administration. Estimates are based on available product characteristics and pharmacological class properties.</p><h4>References</h4><ol><li><p>Ferro Desideri, L, et al., &amp; Traverso, CE (2019). Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. <i>Drugs of today (Barcelona, Spain : 1998)</i> 55(6) 377–384. DOI:<a href=&quot;https://doi.org/10.1358/dot.2019.55.6.2984806&quot;>10.1358/dot.2019.55.6.2984806</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31250842/&quot;>https://pubmed.ncbi.nlm.nih.gov/31250842</a></p></li><li><p>Aihara, M, et al., &amp; Shams, NK (2019). Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study). <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 35(10) 542–550. DOI:<a href=&quot;https://doi.org/10.1089/jop.2019.0044&quot;>10.1089/jop.2019.0044</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31674861/&quot;>https://pubmed.ncbi.nlm.nih.gov/31674861</a></p></li><li><p>Kirihara, T, et al., &amp; Zhang, JZ (2018). Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent. <i>Investigative ophthalmology &amp; visual science</i> 59(1) 145–153. DOI:<a href=&quot;https://doi.org/10.1167/iovs.17-22745&quot;>10.1167/iovs.17-22745</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29332128/&quot;>https://pubmed.ncbi.nlm.nih.gov/29332128</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EX06;
